Pfizer says hemophilia B gene therapy controlled bleeding in key study

Pfizer on Thursday said a gene therapy it’s developing for hemophilia B significantly reduced bleeding in a Phase 3 study of adult men with the uncommon genetic condition. The positive results, which Pfizer summarized in a press release, came slightly earlier than the drugmaker had previously estimated.